COR
NYSE · Health Care
Cencora Inc
$318.03
-7.05 (-2.17%)
Performance
1D
—
1W
—
1M
—
3M
-6.53%
6M
+3.23%
1Y
+16.08%
YTD
-6.15%
Open$324.63
Previous Close$325.08
Day High$326.29
Day Low$316.69
52W High$377.54
52W Low$248.59
Volume—
Avg Volume1.07M
Market Cap69.89B
P/E Ratio43.00
EPS$8.31
SectorHealth Care
Technical Indicators
Full analysis →
SMA 50
$348.35
Below
SMA 200
$318.01
Above
RSI (14)
53.1
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
22 analysts
Price Target
-44.3% upside
Current
$318.03
$318.03
Target
$177.22
$177.22
$132.80
$177.22 avg
$223.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 320.94B | 290.63B | 64.56B |
| Net Income | 1.55B | 1.27B | 3.64B |
| Profit Margin | 0.5% | 0.5% | 5.6% |
| EBITDA | 3.60B | 3.10B | 6.65B |
| Free Cash Flow | — | — | 4.33B |
| Rev Growth | +10.4% | +10.4% | +21.6% |
| Debt/Equity | 5.08 | 5.08 | 0.14 |
Dividend
Dividend Yield0.67%
Annual Dividend$2.25
Payout Ratio28.1%
Frequencyquarterly
Ex-DividendFeb 25, 2026
Pay DateMar 18, 2026
Recent Insider Activity
All Insiders →| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24 | Mauch Robert P. | Exercise | 69,155 | $86.09 | $5.95M |
| Feb 24 | Mauch Robert P. | Sale | 65,393 | $358.94 | $23.47M |
| Feb 24 | Mauch Robert P. | Exercise | 0 | $0.00 | — |
| Feb 20 | Mauch Robert P. | Sale | 65,393 | $359.46 | $23.51M |
| Jan 22 | Mauch Robert P. | Exercise | 71,822 | $86.09 | $6.18M |
About Cencora Inc
Cencora, Inc. is one of the largest pharmaceutical distribution and services companies in the United States, headquartered in Conshohocken, Pennsylvania. The company distributes brand-name and generic pharmaceuticals, specialty drugs, and related healthcare products to a broad network of retail pharmacies, health systems, and physician offices. Cencora also provides consulting, data analytics, and third-party logistics services through its specialty and global subsidiaries. Its scale and distribution reach make it a central player in the U.S. healthcare supply chain, alongside a small number of similarly sized national distributors.
Health Care Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| UNH | UnitedHealth Group Inc | $268.05 | -0.92% | 21.7 | 261.12B |
| ABT | Abbott Laboratories | $104.57 | -0.25% | 28.3 | 184.68B |
| ISRG | Intuitive Surgical Inc | $468.55 | -0.30% | 59.8 | 170.78B |
| SYK | Stryker Corp | $332.68 | +1.54% | 39.5 | 128.28B |
| MDT | Medtronic Plc | $87.67 | -0.25% | 24.1 | 111.30B |
| MCK | Mckesson Corp | $863.56 | -1.84% | 25.1 | 109.03B |
COR Frequently Asked Questions
What does Cencora Inc do?
Cencora is a pharmaceutical logistics powerhouse — it moves drugs from manufacturers to the pharmacies, hospitals, and clinics where patients receive them, handling the cold chain, regulatory compliance, and financial complexity of the pharmaceutical supply chain at enormous scale. The company also provides specialty drug distribution, which involves high-cost biologics and oncology therapies that require specialized handling and reimbursement support. A consulting and data analytics arm generates additional fee-based revenue advising healthcare providers and manufacturers on market access and supply chain strategy.
Is COR stock a good investment?
Pharmaceutical distribution is a scale-driven oligopoly — Cencora, McKesson, and Cardinal Health collectively handle the vast majority of U.S. drug distribution. This structure creates durable competitive positioning and predictable volume growth tied to pharmaceutical spending. Margins are thin but consistent, and the business generates strong cash flow relative to assets. The primary risk is drug pricing reform: government or insurer pressure on pharmaceutical prices could compress the absolute dollar value of drug transactions that Cencora intermediates, even if volume remains stable.
Who are Cencora Inc's main competitors?
McKesson Corporation and Cardinal Health are Cencora's two direct national-scale competitors, together forming a triumvirate that controls the U.S. pharmaceutical wholesale market. All three have similar business models and compete for long-term distribution contracts with major pharmacy chains, hospital systems, and health networks. Outside the U.S., Alliance Healthcare (now Cencora's European subsidiary) competes with Alliance Boots, Phoenix Group, and regional distributors across European pharmaceutical markets.
Does Cencora Inc pay dividends?
Cencora has maintained a regular dividend with modest annual increases, consistent with a business generating steady but thin-margin cash flows at scale. The company supplements its dividend with substantial share repurchases, which have meaningfully reduced the share count over time and been the larger component of total capital return. Given the capital-light nature of distribution relative to manufacturing, Cencora has flexibility to return cash to shareholders while continuing to invest in specialty services expansion and international distribution capabilities.
How much does COR stock cost right now?
COR last closed at $318.03, down 2.17% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $248.59 and a high of $377.54. The current price represents 54% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What is the analyst consensus for COR?
Among 22 analysts covering COR, the consensus rating is Strong Buy — 19 rate it a buy, 3 hold, and 0 sell. The average price target sits at $177.22, implying 44% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
Does Cencora Inc make money?
Cencora Inc generated $320.94B in revenue during fiscal year 2026, with $1.55B reaching the bottom line as net income. The net profit margin of 0.5% reflects the competitive nature of its industry.
Is COR stock expensive based on earnings?
COR trades at a P/E ratio of 43.00 on trailing earnings of $8.31 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
Is COR stock going up or down?
Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -6.53% (3M), +3.23% (6M), +16.08% (1Y), -6.15% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether COR is outperforming or lagging the broader market.